22 Oct 2026
United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
SILVER SPRING, M.D. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company’s Board of Directors has...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2026 financial results in a press release...
Named for Dr. Bartley P. Griffith and Dr. Robert A. Montgomery, pioneers in xenotransplantation, the biosecure facility is purpose-built to manufacture United Therapeutics’ xenokidneys and xenohearts for its rapidly...
The development of a soft mist inhaler (SMI) represents a further advancement of treprostinil delivery devices to potentially address a wider range of patient tolerability profiles
A soft mist formulation may be...
October 14, 2026
United Therapeutics moved quickly over the last week to reach a settlement agreement with Liquidia Technologies, Inc. that enables continuity of therapy for all patients with pulmonary arterial...
A pre-specified subgroup analysis from the phase 3 ADVANCE OUTCOMES study showed that ralinepag reduced the risk of clinical worsening in patients with pulmonary arterial hypertension (PAH), regardless of how many...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the United States District Court for the...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company will utilize the remainder of...
Nebulized Tyvaso® (treprostinil) Inhalation Solution will be the first and only inhaled anti-fibrotic treatment for idiopathic pulmonary fibrosis (IPF) if approved by the U.S. Food and Drug Administration (FDA)
...
01 Sep 2026
United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
United Therapeutics Corporation (Nasdaq: UTHR) announced today that company executives will provide overviews and updates during fireside chat...
ADVANCE OUTCOMES presentations include an analysis showing that ralinepag achieved clinical improvement in a lower risk pulmonary arterial hypertension (PAH) population and reduced clinical worsening in PAH patients...
Ralinepag has the potential to redefine the PAH treatment landscape as the first and only once-daily oral prostacyclin, if approved by the U.S. Food and Drug Administration (FDA)Ralinepag combines potent receptor...